Drugs Made In America Acquisition Corp. Units (DMAAU) — Financial Flexibility Index

Latest as of March 2026: -0.02x

Drugs Made In America Acquisition Corp. Units (DMAAU) has a Financial Flexibility Index of -0.02x as of March 2026. Free cash flow of $-125.18K (operating CF $-125.18K minus capex $0.00) represents 0% of total liabilities ($7.28 Million).

Financial Flexibility Index

-0.02x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-125.18K
Operating CF − Capex

Total Liabilities

$7.28 Million
USD

Capital Expenditures

$0.00
USD

Drugs Made In America Acquisition Corp. Units Financial Flexibility Index (2024–2025)

Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Units across 2 annual periods. See Drugs Made In America Acquisition Corp. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for Drugs Made In America Acquisition Corp. Units (2024–2025)

Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Units. For the full company profile including market capitalisation, see Drugs Made In America Acquisition Corp. stock valuation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.07x $-539.19K $-539.19K $7.28 Million ▲ +100.0%
2024 -216.50x $-172.26K $-172.26K $795.67
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities